Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis

nooshin dalili

Status: Completed

Conditions: Hemodialysis Complication

Treatments: Dietary Supplement: Lactobacillus rhamnosus; Drug: Placebo - Cap

Study type: Interventional

Funder types: Other

Identifiers

NCT03527680

IRCT20154182017N21

Details and patient eligibility

About

Uremic toxins such as p-cresol and phenol are suggested to be associated with higher mortality in hemodialysis patients. The aim of this study was to investigate the effects of probiotics on serum p-cresol level in hemodialysis patients.

Full description

Overall, 42 hemodialysis patients (10 women and 32 men) were divided randomly into the Lactobacillus rhamnosus group (21 patients) and the placebo group (21 patients).

Enrollment: 42 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:• Age more than 20 years

• Acceptable performance of alimentary system
• Ability to drink at least 200 ml of water per day
• No history of being allergic to fungi and yeast
• Absence of acute medical illness
• life expectancy more than 3 months
• Accept and sign the consent

Exclusion Criteria:

• Patient's unwillingness to participate in the study
• History of smoking, peritoneal dialysis (PD) or previous kidney transplantation
• Lactation or pregnancy
• Drug history including antibiotics, prebiotics, probiotics, herbal drugs, psychedelic drugs, flavors.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

42 participants in 2 patient groups, including a placebo group

Lactobacillus rhamnosus

Experimental group

Description:

received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus

Treatment:

Dietary Supplement: Lactobacillus rhamnosus

Placebo

Placebo Comparator group

Description:

received one placebo capsule per day Infant formula after meal for 28 days

Treatment:

Drug: Placebo - Cap